ADMA Biologics Community

11-NOV-2024 Actual company guidance: 2024: 415 MUSD revenue (S24) and net income 120 MUSD (E24), 2025: 465 MUSD (S25), 165 MUSD net income (E25) Market cap of 5.35 BUSD (P) at 22.62/share: P/S24 = 12.9, P/E24 = 44.6, P/S25 = 11.5 and P/E25 = 32.4) My assumptions: ADMA will be highly profitable due to high ratio of hyperimmunes (maybe eventually they will only manufacture hyperimmunes if S. pneumonia is successful and provided they can source the required amount of hyperimmune plasma).

Key Takeaways Heavy dependence on a limited product range and potential reimbursement cuts expose ADMA to risks in revenue stability and margin durability. Advances in alternative therapies and increased pricing pressure from healthcare consolidation may limit long-term growth and profitability.

Key Takeaways Enhanced production and increased plasma supply are set to boost revenue and earnings growth, with long-term revenue potential exceeding projections. ASCENIV and SG-001 are strategically positioned to expand market share and drive high-margin growth, supporting a robust financial outlook.

Key Takeaways Major increases in plasma supply and production efficiency, combined with expanding ASCENIV demand, will drive significant revenue and margin growth. Strong intellectual property and regulatory barriers support premium pricing and long-term profit expansion in a market with rising plasma therapeutic needs.